Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Exubera: So far no evidence available of an additional therapeutic benefit

10.05.2006


IQWiG publishes a comparative review of inhaled insulin versus insulin administered subcutaneously



There is currently no evidence available that inhaled insulin (Exubera) in diabetes therapy shows advantages over short-acting human insulin or insulin analogues administered subcutaneously. The available studies do not provide evidence that Exubera would improve the quality of life or treatment satisfaction of diabetes patients in Germany. However, they do provide indications of disadvantages of Exubera therapy, for example, an increase in severe hypoglycaemia rates. This is the result of the first Rapid Report produced by the Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG) on 4 May 2006, which was commissioned by the Federal Joint Committee on 17 November 2005.

For this Rapid Report, outcomes were selected which enabled the comparison of Exubera versus insulin administered subcutaneously with regard to patient-relevant endpoints. The endpoints assessed included quality of life, treatment satisfaction, glycaemic control (changes in HbA1c values), hypoglycaemia rates, adverse drug effects, and prevention of late complications.


Possible higher risk of severe hypoglycaemia with Exubera therapy

No studies were identified in which inhaled insulin was compared with insulin administered subcutaneously in patients with type 2 diabetes, within an identical therapeutic regime. In the only comparator study identified, the therapeutic regimes investigated were different (intensified versus conventional insulin therapy). In this study, even though the reductions in blood glucose levels were comparable between treatment groups, a tendency towards a higher incidence of severe hypoglycaemia was shown in patients treated with Exubera.

According to current knowledge, Exubera is not a safe alternative, either, for patients with type 1 diabetes. IQWiG’s comprehensive literature search only identified two studies in which inhaled insulin was compared with insulin administered subcutaneously, within an identical therapeutic regime (intensified insulin therapy). These studies also showed a higher incidence of severe hypoglycaemia in patients treated with Exubera (even though the reductions in blood glucose levels were comparable between treatment groups).

Long-term risks of Exubera therapy unclear

With regard to adverse drug effects, a higher incidence of cough and formation of insulin antibodies was shown with Exubera therapy. On the basis of the data available, it cannot be excluded that long-term Exubera therapy may lead to pulmonary damage. On the contrary: inconsistent study results and the Summary of Product Characteristics provided by the European Medicines Agency (EMEA) in fact indicate a risk potential of Exubera. People who smoke or suffer from pulmonary diseases have so far been excluded from participating in studies on Exubera.

No valid statements on treatment satisfaction and quality of life

Although it is possible to reduce the number of subcutaneous injections with Exubera, they cannot be totally avoided, if the additional administration of basal insulin is necessary. Moreover, regular self-measurement of blood glucose levels by skin prick is still necessary. It cannot be inferred from the studies available that this new way of administering insulin generally improves treatment satisfaction or quality of life in affected patients. On the one hand, these aspects were not or were only insufficiently described in the available publications, although the respective parameters were investigated. On the other hand, the relevance of the available data is limited with regard to Germany, as it appears that Exubera was not compared with insulin administered subcutaneously with pen systems (which is a widespread type of administration in Germany). Instead, it appears that Exubera was compared with insulin administered subcutaneously with syringes for self-filling.

IQWiG does not see its Rapid Report as a conclusive evaluation. IQWiG recommends further evaluations of Exubera and the consideration of previously unpublished data from studies in a next step, provided that the manufacturer supplies them. Furthermore, open issues need to be clarified in an adequately designed randomised intervention study before Exubera is widely prescribed in Germany.

Background on Rapid Reports

The assignment to assess the therapeutic benefit of inhaled insulin was conducted in an accelerated manner by means of a Rapid Report. In contrast to the conventional procedure, a preliminary report is not published during the production of a Rapid Report. A preliminary version of the Rapid Report is reviewed by an external expert. A scientific hearing where interested parties can provide comments is however not conducted. Furthermore, as timelines for publication do not need to be adhered to, the whole procedure is less time-consuming. Primarily, a Rapid Report serves to help the Federal Joint Committee and other organisations form an opinion on a topic. The Federal Joint Committee issues directives for health care services (including the prescription of pharmaceuticals) reimbursed by the statutory health insurance (SHI) funds.

Dr. Anna-Sabine Ernst | EurekAlert!
Further information:
http://www.iqwig.de

More articles from Studies and Analyses:

nachricht The importance of biodiversity in forests could increase due to climate change
17.11.2017 | Deutsches Zentrum für integrative Biodiversitätsforschung (iDiv) Halle-Jena-Leipzig

nachricht Win-win strategies for climate and food security
02.10.2017 | International Institute for Applied Systems Analysis (IIASA)

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New proton record: Researchers measure magnetic moment with greatest possible precision

High-precision measurement of the g-factor eleven times more precise than before / Results indicate a strong similarity between protons and antiprotons

The magnetic moment of an individual proton is inconceivably small, but can still be quantified. The basis for undertaking this measurement was laid over ten...

Im Focus: Frictional Heat Powers Hydrothermal Activity on Enceladus

Computer simulation shows how the icy moon heats water in a porous rock core

Heat from the friction of rocks caused by tidal forces could be the “engine” for the hydrothermal activity on Saturn's moon Enceladus. This presupposes that...

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

IceCube experiment finds Earth can block high-energy particles from nuclear reactions

24.11.2017 | Physics and Astronomy

A 'half-hearted' solution to one-sided heart failure

24.11.2017 | Health and Medicine

Heidelberg Researchers Study Unique Underwater Stalactites

24.11.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>